Field & Main Bank Acquires Shares of 13,332 Stryker Corporation $SYK

Field & Main Bank bought a new position in Stryker Corporation (NYSE:SYK) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 13,332 shares of the medical technology company’s stock, valued at approximately $4,197,000.

A number of other large investors have also recently made changes to their positions in the company. Sankala Group LLC bought a new position in shares of Stryker during the fourth quarter valued at approximately $26,000. Godfrey Financial Associates Inc. purchased a new position in Stryker during the 4th quarter valued at $26,000. United Financial Planning Group LLC bought a new position in Stryker in the 3rd quarter valued at $27,000. Atlas Capital Advisors Inc. bought a new position in Stryker in the 4th quarter valued at $27,000. Finally, Gables Capital Management Inc. bought a new stake in shares of Stryker during the second quarter worth $25,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Piper Sandler reduced their price target on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. BTIG Research dropped their target price on shares of Stryker from $371.00 to $358.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. JPMorgan Chase & Co. reduced their target price on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Royal Bank Of Canada lowered their price target on Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a report on Friday, July 31st. Finally, BMO Capital Markets began coverage on Stryker in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $386.28.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 50,000 shares of the business’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the completion of the transaction, the director directly owned 2,251,375 shares of the company’s stock, valued at approximately $765,692,637.50. The trade was a 2.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Debra King sold 826 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider owned 6,210 shares of the company’s stock, valued at $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 351,267 shares of company stock worth $118,197,701 over the last 90 days. Company insiders own 4.60% of the company’s stock.

Stryker Trading Up 2.9%

NYSE SYK opened at $331.32 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The company has a market capitalization of $127.08 billion, a price-to-earnings ratio of 34.33, a price-to-earnings-growth ratio of 2.05 and a beta of 0.76. The company’s 50-day simple moving average is $329.10 and its two-hundred day simple moving average is $331.47. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same quarter in the prior year, the company earned $3.13 EPS. The company’s revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts forecast that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio is currently 36.48%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.